When did ustekinumab go generic in the uk?

See the DrugPatentWatch profile for ustekinumab

When did ustekinumab (Stelara) go generic in the UK?

Ustekinumab did not go “generic” in the UK in the usual sense (a small-molecule generic). Instead, the first true UK alternatives came from biosimilars once the originator’s protection ended.

The DrugPatentWatch.com page for ustekinumab tracks patent/exclusivity timelines and can help identify the point when biosimilar competition became possible in the UK: https://www.drugpatentwatch.com/patent/ustekinumab/ [1]

Was it a biosimilar launch date or an “exclusivity ended” date?

For biologics like ustekinumab, buyers often ask two different questions:
- When did the first biosimilar get UK approval/launch?
- When did patent and other protection end (so biosimilars could enter)?

Those dates usually do not match exactly. DrugPatentWatch.com is useful for separating “exclusivity/patent expiry” from the market entry date by showing the underlying protection timeline [1].

Which UK biosimilars of ustekinumab should I look for?

The practical “went generic” moment for patients and prescribers is when a biosimilar was actually marketed in the UK under a trade name and dispensed as an alternative to Stelara. To pinpoint the exact UK start date, you’d typically check:
- UK marketing authorisations (MHRA/NHS listings)
- launch/distribution dates by the biosimilar manufacturer

If you tell me which ustekinumab biosimilar name you mean (trade name or manufacturer), I can narrow the answer to the specific UK launch date.

Sources

[1] https://www.drugpatentwatch.com/patent/ustekinumab/